Hyeonjung Park

Hyeonjung Park

Auto-generated profile, based on publicly available information

Hyeonjung Park

Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2025 in Journal of Medical Internet Research
Verified
Journal Article
Open access
HPHyeonjung Park
Hyeonjung Park
MJMinseol Jang
Minseol Jang
DKDaehyun Kim
Daehyun Kim
CKChul Kim
Chul Kim
JSJun Hyeong Song
Jun Hyeong Song
HSHae Sun Suh
Hae Sun Suh
Background: Pulmonary rehabilitation, a nonpharmacological treatment for chronic respiratory diseases, is underused due to limited access and time constraints. In a randomized controlled trial, the digital therapeutics (DTx) demonstrated superior efficacy to standard treatment. However, evidence on the cost-effectiveness of DTx and appropriate pricing strategies remains limited. Objective: This study aimed to evaluate the cost-effectiveness of DTx through cost-utility analysis and to explore a value-based price for its implementation. Methods: An economic evaluation was based on an 8-week randomized controlled trial involving 84 participants assigned to either the DTx group or standard treatment group. Costs were estimated from a health care system perspective. Quality-adjusted life years (QALYs) were estimated by using mapping algorithms from the chronic obstructive pulmonary disease assessment test to EQ-5D-3L. Cost-utility analysis was conducted to estimate the incremental cost-utility ratio (ICUR), which represents the additional cost per QALY gained. The willingness-to-pay threshold was set at US $19,410 per QALY. Sensitivity analyses included probabilistic sensitivity analysis, deterministic sensitivity analysis, and subgroup and scenario analyses, including a 1-year Markov model. Results: Compared with standard treatment, DTx increased QALY by 0.0096 at an additional cost of US $85.33, resulting in an ICUR of US $8890 per QALY gained. The maximum value-based price for an 8-week DTx program was estimated at US $192. In probabilistic sensitivity analysis, DTx had a 60.2% probability of being cost-effective at the set willingness-to-pay threshold, with 88.6% of iterations in the northeast quadrant falling below the threshold. The deterministic sensitivity analysis showed that ICURs remained below the willingness-to-pay threshold under all tested assumptions, with the maximum ICUR (US $15,644/QALY) also staying below the threshold. Subgroup analysis confirmed cost-effectiveness in both older adults (≥65 y) and non–older adults (<65 y) populations, and in both chronic obstructive pulmonary disease and interstitial lung disease groups. The 1-year Markov model estimated an ICUR of US $4398 per QALY. Conclusions: DTx for pulmonary rehabilitation demonstrated the cost-effectiveness compared with standard treatment. These findings support its potential for improving outcomes in patients with chronic respiratory disease and provide a pricing framework to facilitate its integration into health care systems.

17 March 2025 in JMIR Preprints
Verified
Preprint
Open access
HPHyeonjung Park
Hyeonjung Park
MJMinseol Jang
Minseol Jang
DKDaehyun Kim
Daehyun Kim
CKChul Kim
Chul Kim
JSJun Hyeong Song
Jun Hyeong Song
HSHae Sun Suh
Hae Sun Suh
BACKGROUND Pulmonary rehabilitation, a nonpharmacological treatment for chronic respiratory diseases, is underused due to limited access and time constraints. In a randomized controlled trial, the digital therapeutics (DTx) demonstrated superior efficacy to standard treatment. However, evidence on the cost-effectiveness of DTx and appropriate pricing strategies remains limited. OBJECTIVE This study aimed to evaluate the cost-effectiveness of DTx through cost-utility analysis and to explore a value-based price for its implementation. METHODS An economic evaluation was based on an 8-week randomized controlled trial involving 84 participants assigned to either the DTx group or standard treatment group. Costs were estimated from a health care system perspective. Quality-adjusted life years (QALYs) were estimated by using mapping algorithms from the chronic obstructive pulmonary disease assessment test to EQ-5D-3L. Cost-utility analysis was conducted to estimate the incremental cost-utility ratio (ICUR), which represents the additional cost per QALY gained. The willingness-to-pay threshold was set at US $19,410 per QALY. Sensitivity analyses included probabilistic sensitivity analysis, deterministic sensitivity analysis, and subgroup and scenario analyses, including a 1-year Markov model. RESULTS Compared with standard treatment, DTx increased QALY by 0.0096 at an additional cost of US $85.33, resulting in an ICUR of US $8890 per QALY gained. The maximum value-based price for an 8-week DTx program was estimated at US $192. In probabilistic sensitivity analysis, DTx had a 60.2% probability of being cost-effective at the set willingness-to-pay threshold, with 88.6% of iterations in the northeast quadrant falling below the threshold. The deterministic sensitivity analysis showed that ICURs remained below the willingness-to-pay threshold under all tested assumptions, with the maximum ICUR (US $15,644/QALY) also staying below the threshold. Subgroup analysis confirmed cost-effectiveness in both older adults (≥65 y) and non–older adults (<65 y) populations, and in both chronic obstructive pulmonary disease and interstitial lung disease groups. The 1-year Markov model estimated an ICUR of US $4398 per QALY. CONCLUSIONS DTx for pulmonary rehabilitation demonstrated the cost-effectiveness compared with standard treatment. These findings support its potential for improving outcomes in patients with chronic respiratory disease and provide a pricing framework to facilitate its integration into health care systems.